Postoperative PainPhase 4NCT03597997
Effects of TIVA With Propofol Versus Inhalational Anaesthesia on Postoperative Pain After Hepatectomy
A Phase 4 study testing Propofol and Sevoflurane in people with Postoperative Pain, run by The University of Hong Kong at 2 sites in Hong Kong.
Trial summary
Propofol is a commonly used intravenous anaesthetic drugs both for induction and maintenance of general anaesthesia. Advantages of total intravenous anaesthesia (TIVA) with propofol include reduced nausea and vomiting, reduced atmospheric pollution, and better wake up profile. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Postoperative Pain
- What is being tested?
- Propofol and Sevoflurane
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 90 participants
- Where
- 2 sitesHong Kong
- Study dates
- 27 Aug 2018to 1 Dec 2021
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- ASA I to III
- Scheduled for elective hepatectomy (left or right hepatectomy, segmentectomy, or wedge resection)
Who cannot join
- Known drug allergy to propofol, opioids, non-steroidal anti-inflammatory drugs (NSAIDs) including COX-2 inhibitors, paracetamol, ketamine
- Alcohol or drug abuse
- Impaired renal function, defined as preoperative serum creatinine level over 120µmol/L
- Impaired or retarded mental state
- BMI > 35kg/m2
- History of chronic pain
Show all 11Show fewer
- Pregnancy
- Local infection
- History of psychosis, delirium
- Chronic opioid user
- Patient refusal
Trial locations and contacts
2 sites in 1 country.
Hong Kong2 sites
Queen Mary Hospital
Hong Kong
The University of Hong Kong
Hong Kong
About this study
Official title: Effects of Intraoperative Total Intravenous Anaesthesia (TIVA) With Propofol Versus Inhalational Anaesthesia on Postoperative Pain After Hepatectomy: a Randomized Controlled Trial
Propofol is a commonly used intravenous anaesthetic drugs both for induction and maintenance of general anaesthesia. Advantages of total intravenous anaesthesia (TIVA) with propofol include reduced nausea and vomiting, reduced atmospheric pollution, and better wake up profile. But the need for a reliable intravenous access, specialized pumps, pain on injection and potential concerns regarding awareness are potential disadvantages of TIVA propofol.
Results from clinical trials have not been consistent. Some randomized trials have shown improved analgesia with TIVA propofol, and some reported no significant difference. A meta-analysis found that propofol was associated with a statistically significant reduction pain scores 24 hours after surgery. However, the clinical effect size was small. Therefore, the usefulness of propofol as an analgesic adjunct is still inconclusive.
Read more
Whether TIVA propofol is useful in providing significant postoperative analgesia may be influenced by the type of surgery and accompanying analgesic regime. This agrees with the concept of procedure specific analgesia. Liver surgery produces moderate to severe pain as a result of an upper abdominal incision. Pain control can be difficult due to concerns with epidural analgesia in patients with potential clotting abnormalities and the effect of analgesic metabolism as a in patients with liver dysfunction. Results from our retrospective study showed that TIVA propofol was associated with reduced pain scores with coughing on postoperative days 1 and 2, and also reduced opioid consumption when compared with sevoflurane after liver surgery.
In this study, the investigators plan to conduct a randomized controlled trial to further determine whether TIVA propofol reduces acute postoperative pain and opioid consumption after hepatectomy.
Read the detailed description
- Preoperative care
Assessment will be done at the preadmission clinic or at the general ward. Fasting for patients will start at midnight before operation. Sedative premedication will not be prescribed.
- Anaesthesia and intraoperative care
= Group S (sevoflurane) - Patients from group S will be anaesthetized by inhalational anaesthesia using sevoflurane, according to the following protocol:
On arrival to the operation theatre, a 20 or 22 gauge intravenous cannula will be inserted. Standard monitoring with pulse oximeter, non-invasive blood pressure, and three lead electrocardiogram will be applied prior to induction. Non-invasive blood pressure will be checked at least every 5 minutes throughout the operation.
Propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously (IV) for induction of general anaesthesia. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to maintain a BIS value of between 40-60. Intravenous remifentanil infusion between 0.1-0.2 mcg/kg/min will be given and this will be titrated to provide optimal haemodynamic parameters. Muscle relaxants can be given during the operation as required.
Intravenous phenylephrine, ephedrine or fluid administration with colloid or crystalloid will be given at the discretion of the anaesthesiologist for management of hypotension. Hypertension or tachycardia will be managed by titrating the remifentanil infusion up to 0.2mcg/kg/min or sevoflurane up to 1.5 MAC. Intravenous anti hypertensive agents such as beta blockers (eg. esmolol, labetolol), hydralazine, glyceryl trinitrate, and phentolamine can be given if hypertension persists.
Thermal blanket will be used with the aim of keeping a core temperature of 35.5-37.5 degrees Celsius. Ondansetron 4mg IV will be given 30 minutes before end of surgery.
Sevoflurane and remifentanil infusion will be switched off at the end of the procedure. Reversal of muscle relaxation can be obtained if required with neostigmine 50mcg/kg IV and atropine 20mcg/kg IV after the operation. Patients will subsequently be transferred to the post anaesthetic care unit (PACU) for monitoring for at least 30 minutes.
= Group P (propofol) - Patients in group P will be anaesthetized using total intravenous propofol, according to the following protocol:
Monitoring and other anaesthetic procedures including the management of hypertension and hypotension will be the same as group S. The only difference is that induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Sevoflurane will not be used, and oxygen and air would be given to provide a FiO2 of 30-50%.
Target controlled infusion (TCI) with modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia. Level of anaesthesia will be titrated to produce a BIS value of between 40-60. During induction of general anaesthesia, remifentanil 0.5-1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be given intravenously (IV). Remifentanil will be infused at a rate of between 0.1-0.2mcg/kg/min during maintenance of anaesthesia.
- Analgesic modalities and pain assessment
Both groups (Groups S and P)
Morphine sulphate at a bolus dose of 0.1mg/kg will be given intravenously before skin incision. Additional 0.1mg/kg of morphine sulphate can be given in divided doses when the surgery has continued for more than 2 hours at the discretion of the anaesthetist. Ketamine 0.5mg/kg intravenously will be given before skin incision. Patients will receive local wound infiltration with up to 2mg/kg of levobupivicaine during wound closure.
Resting pain scores will be checked every 5 minutes in the post anaesthetic care unit. 2mg boluses of intravenous morphine sulphate will be given every 5 minutes until the NRS pain score is less than 4/10. Respiratory rate, oxygen saturation, Ramsay sedation scores, blood pressure and heart rate will be monitored every 5 minutes while the patient is in the post anaesthetic care unit. A PCA morphine machine will be connected to the patient once the NRS pain score is less than 4/10. The PCA morphine machine will be set to give 1mg of intravenous morphine sulphate with each patient demand, and lockout duration of 5 minutes will be set. Maximum dose limit will be 0.1mg/kg of morphine sulphate per hour and basal infusion will not be given.
When the patient resumes fluid diet in the ward on postoperative day 0, regular oral dihydrocodeine will be prescribed at a dose of 30mg tds for two days. Afterwards, dihydrocodeine will be given as needed. Breakthrough pain will be treated by intramuscular/subcutaneous morphine 0.1mg/kg every 4 hours as needed starting from postoperative day 0.
Respiratory rate, oxygen saturation, sedation scores will be monitored every hour while patient is using PCA morphine. Blood pressure and heart rate will be measured every 4 hours. Pain related parameters like the numerical rating scales (NRS) pain scores at rest and during cough, cumulative PCA morphine doses and number of PCA demands/goods delivered, and side effects will also be recorded very 4 hours. Anaesthesiologists will assess patients every day to determine the adequacy of analgesia.
PCA morphine will be given for at least 2 days. PCA morphine will be stopped on postoperative day 2 if NRS pain scores during cough is less than 4/10 and morphine consumption is low. If PCA morphine consumption is high or NRS pain scores during cough is equal or greater than 4, PCA morphine will be continued. Assessment will be performed everyday. An NRS pain score that is 4 or higher during coughing on postoperative day 5 will require an evaluation for complications. The patient will be further managed at the discretion of the anaesthesiologist. After discontinuation of PCA morphine, NRS pain scores (at rest and with coughing) and the dose and frequency of rescue analgesia used will be recorded daily until patient discharge.
NRS pain score and satisfaction with analgesia (scored from 0-10, where 0 is the least satisfaction and 10 most satisfaction) will be obtained.
Quality of recovery 9 (QoR-9) is measured at 24h and 72h after surgery. The attending surgeon will determine final hospital discharge
- A brief home telephone interview will be conducted at 3 and 6 months to assess the incidence of chronic pain. The severity of pain, if present, would be recorded using NRS (0-10) at rest and with coughing. Other information that will be obtained at 3 and 6 months after surgery include HRQOL obtained with the Chinese-HK version of the SF12v2- health survey and psychological condition will be assessed with the Hospital Anxiety and Depression Scale (HADS) questionnaire.
- Conditions
- Postoperative Pain
- Being tested
- Propofol, Sevoflurane
- Keywords
- Postoperative pain, Total intravenous anaesthesia, TIVA, Propofol, Hepatectomy
- Medical subject headings
- Pain, Postoperative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PropofolDrug
Target controlled infusion (TCI) with modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia. Monitoring and other anaesthetic procedures including the management of hypertension and hypotension in group P will be the same as group S. The only difference is that induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Oxygen and air would be given to provide a FiO2 of 30-50%.
SevofluraneDrug
Propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously for induction of general anaesthesia. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to maintain a BIS value of between 40-60. Intravenous remifentanil infusion between 0.1-0.2 mcg/kg/min will be given and this will be titrated to provide optimal haemodynamic parameters.
| Study group | Role | What they receive |
|---|---|---|
| Group P | Experimental | The patients in group (P) will be anaesthetized using total intravenous propofol. Receives: Drug: Propofol |
| Group S | Sham comparator | Patients in group (S) will be anaesthetized by inhalational anaesthesia using sevoflurane. Receives: Drug: Sevoflurane |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain assessed by numercial rating scales (NRS) pain scores
NRS pain scores (from 0-10, where 0 is the least satisfaction and 10 most satisfaction) will be recorded at rest and with coughing everyday.
Measured: at postoperative day 1
Secondary outcomes (3)
PCA morphin consumption
Cumulative PCA morphine doses (in mg) will be recorded daily based on medical record.
Measured: from postoperative day 0 until postoperative day 5
Dihydrocodeine use
Frequency of dihydrocodeine use (i.e. how many times per day) will be recorded daily according to medical record.
Measured: from postoperative day 0 until postoperative day 5
Side effects of analgesics
Pruritus, dizziness, nausea, vomiting, wound infection, urinary retention, confusion, constipation will be recorded
Measured: from postoperative day 0 until postoperative day 5
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jul 2018
- Study start27 Aug 2018
- Primary completion15 Jul 2021
- Study completion1 Dec 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Postoperative PainStudies of the same condition, open and under way.
- More trials run by The University of Hong KongThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Patients in one group (S) will be anaesthetized by inhalational anaesthesia using sevoflurane. The patients in the second group (P) will be anaesthetized using total intravenous propofol.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- The University of Hong Kong
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Wong Sau Ching Stanley, The University of Hong Kong
- Investigators
- Stanley SC Wong, MBBS, Principal investigator, The University of Hong Kong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03597997
- Sponsor's protocol ID
- UW18-176
- Status last verified
- Oct 2022
- First submitted
- 28 Jun 2018
- Last updated
- 13 Oct 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Wong SSC, Wang F, Chan TCW, Cheung CW. The analgesic effect of total intravenous anaesthesia with propofol versus inhalational anaesthesia for acute postoperative pain after hepatectomy: a randomized controlled trial. BMC Anesthesiol. 2023 Apr 3;23(1):112. doi: 10.1186/s12871-023-02063-7.
PubMed 37013472
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Intraoperative Total Intravenous Anaesthesia (TIVA) With Propofol Versus Inhalational Anaesthesia on Postoperative Pain After Hepatectomy: a Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT03597997
- Acronym / sponsor ID
- UW18-176
- Conditions
- Postoperative Pain
- Keywords
- Postoperative pain, Total intravenous anaesthesia, TIVA, Propofol, Hepatectomy
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- The University of Hong KongUniversity, hospital or other
- Study start
- 27 Aug 2018 (actual)
- Primary completion
- 15 Jul 2021 (actual)
- Study completion
- 1 Dec 2021 (actual)
- First posted
- 24 Jul 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Propofol is a commonly used intravenous anaesthetic drugs both for induction and maintenance of general anaesthesia. Advantages of total intravenous anaesthesia (TIVA) with propofol include reduced nausea and vomiting, reduced atmospheric pollution, and better wake up profile. But the need for a reliable intravenous access, specialized pumps, pain on injection and potential concerns regarding awareness are potential disadvantages of TIVA propofol.
Results from clinical trials have not been consistent. Some randomized trials have shown improved analgesia with TIVA propofol, and some reported no significant difference. A meta-analysis found that propofol was associated with a statistically significant reduction pain scores 24 hours after surgery. However, the clinical effect size was small. Therefore, the usefulness of propofol as an analgesic adjunct is still inconclusive.
Whether TIVA propofol is useful in providing significant postoperative analgesia may be influenced by the type of surgery and accompanying analgesic regime. This agrees with the concept of procedure specific analgesia. Liver surgery produces moderate to severe pain as a result of an upper abdominal incision. Pain control can be difficult due to concerns with epidural analgesia in patients with potential clotting abnormalities and the effect of analgesic metabolism as a in patients with liver dysfunction. Results from our retrospective study showed that TIVA propofol was associated with reduced pain scores with coughing on postoperative days 1 and 2, and also reduced opioid consumption when compared with sevoflurane after liver surgery.
In this study, the investigators plan to conduct a randomized controlled trial to further determine whether TIVA propofol reduces acute postoperative pain and opioid consumption after hepatectomy.
Detailed description
- Preoperative care
Assessment will be done at the preadmission clinic or at the general ward. Fasting for patients will start at midnight before operation. Sedative premedication will not be prescribed.
- Anaesthesia and intraoperative care
= Group S (sevoflurane) - Patients from group S will be anaesthetized by inhalational anaesthesia using sevoflurane, according to the following protocol:
On arrival to the operation theatre, a 20 or 22 gauge intravenous cannula will be inserted. Standard monitoring with pulse oximeter, non-invasive blood pressure, and three lead electrocardiogram will be applied prior to induction. Non-invasive blood pressure will be checked at least every 5 minutes throughout the operation.
Propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously (IV) for induction of general anaesthesia. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to maintain a BIS value of between 40-60. Intravenous remifentanil infusion between 0.1-0.2 mcg/kg/min will be given and this will be titrated to provide optimal haemodynamic parameters. Muscle relaxants can be given during the operation as required.
Intravenous phenylephrine, ephedrine or fluid administration with colloid or crystalloid will be given at the discretion of the anaesthesiologist for management of hypotension. Hypertension or tachycardia will be managed by titrating the remifentanil infusion up to 0.2mcg/kg/min or sevoflurane up to 1.5 MAC. Intravenous anti hypertensive agents such as beta blockers (eg. esmolol, labetolol), hydralazine, glyceryl trinitrate, and phentolamine can be given if hypertension persists.
Thermal blanket will be used with the aim of keeping a core temperature of 35.5-37.5 degrees Celsius. Ondansetron 4mg IV will be given 30 minutes before end of surgery.
Sevoflurane and remifentanil infusion will be switched off at the end of the procedure. Reversal of muscle relaxation can be obtained if required with neostigmine 50mcg/kg IV and atropine 20mcg/kg IV after the operation. Patients will subsequently be transferred to the post anaesthetic care unit (PACU) for monitoring for at least 30 minutes.
= Group P (propofol) - Patients in group P will be anaesthetized using total intravenous propofol, according to the following protocol:
Monitoring and other anaesthetic procedures including the management of hypertension and hypotension will be the same as group S. The only difference is that induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Sevoflurane will not be used, and oxygen and air would be given to provide a FiO2 of 30-50%.
Target controlled infusion (TCI) with modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia. Level of anaesthesia will be titrated to produce a BIS value of between 40-60. During induction of general anaesthesia, remifentanil 0.5-1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be given intravenously (IV). Remifentanil will be infused at a rate of between 0.1-0.2mcg/kg/min during maintenance of anaesthesia.
- Analgesic modalities and pain assessment
Both groups (Groups S and P)
Morphine sulphate at a bolus dose of 0.1mg/kg will be given intravenously before skin incision. Additional 0.1mg/kg of morphine sulphate can be given in divided doses when the surgery has continued for more than 2 hours at the discretion of the anaesthetist. Ketamine 0.5mg/kg intravenously will be given before skin incision. Patients will receive local wound infiltration with up to 2mg/kg of levobupivicaine during wound closure.
Resting pain scores will be checked every 5 minutes in the post anaesthetic care unit. 2mg boluses of intravenous morphine sulphate will be given every 5 minutes until the NRS pain score is less than 4/10. Respiratory rate, oxygen saturation, Ramsay sedation scores, blood pressure and heart rate will be monitored every 5 minutes while the patient is in the post anaesthetic care unit. A PCA morphine machine will be connected to the patient once the NRS pain score is less than 4/10. The PCA morphine machine will be set to give 1mg of intravenous morphine sulphate with each patient demand, and lockout duration of 5 minutes will be set. Maximum dose limit will be 0.1mg/kg of morphine sulphate per hour and basal infusion will not be given.
When the patient resumes fluid diet in the ward on postoperative day 0, regular oral dihydrocodeine will be prescribed at a dose of 30mg tds for two days. Afterwards, dihydrocodeine will be given as needed. Breakthrough pain will be treated by intramuscular/subcutaneous morphine 0.1mg/kg every 4 hours as needed starting from postoperative day 0.
Respiratory rate, oxygen saturation, sedation scores will be monitored every hour while patient is using PCA morphine. Blood pressure and heart rate will be measured every 4 hours. Pain related parameters like the numerical rating scales (NRS) pain scores at rest and during cough, cumulative PCA morphine doses and number of PCA demands/goods delivered, and side effects will also be recorded very 4 hours. Anaesthesiologists will assess patients every day to determine the adequacy of analgesia.
PCA morphine will be given for at least 2 days. PCA morphine will be stopped on postoperative day 2 if NRS pain scores during cough is less than 4/10 and morphine consumption is low. If PCA morphine consumption is high or NRS pain scores during cough is equal or greater than 4, PCA morphine will be continued. Assessment will be performed everyday. An NRS pain score that is 4 or higher during coughing on postoperative day 5 will require an evaluation for complications. The patient will be further managed at the discretion of the anaesthesiologist. After discontinuation of PCA morphine, NRS pain scores (at rest and with coughing) and the dose and frequency of rescue analgesia used will be recorded daily until patient discharge.
NRS pain score and satisfaction with analgesia (scored from 0-10, where 0 is the least satisfaction and 10 most satisfaction) will be obtained.
Quality of recovery 9 (QoR-9) is measured at 24h and 72h after surgery. The attending surgeon will determine final hospital discharge
- A brief home telephone interview will be conducted at 3 and 6 months to assess the incidence of chronic pain. The severity of pain, if present, would be recorded using NRS (0-10) at rest and with coughing. Other information that will be obtained at 3 and 6 months after surgery include HRQOL obtained with the Chinese-HK version of the SF12v2- health survey and psychological condition will be assessed with the Hospital Anxiety and Depression Scale (HADS) questionnaire.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- Patients in one group (S) will be anaesthetized by inhalational anaesthesia using sevoflurane. The patients in the second group (P) will be anaesthetized using total intravenous propofol.
| Arm | Type | Receives |
|---|---|---|
| Group P | Experimental | Drug: PropofolThe patients in group (P) will be anaesthetized using total intravenous propofol. |
| Group S | Sham comparator | Drug: SevofluranePatients in group (S) will be anaesthetized by inhalational anaesthesia using sevoflurane. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- ASA I to III
- Scheduled for elective hepatectomy (left or right hepatectomy, segmentectomy, or wedge resection)
Key exclusion criteria (11 listed)
- Known drug allergy to propofol, opioids, non-steroidal anti-inflammatory drugs (NSAIDs) including COX-2 inhibitors, paracetamol, ketamine
- Alcohol or drug abuse
- Impaired renal function, defined as preoperative serum creatinine level over 120µmol/L
- Impaired or retarded mental state
- BMI > 35kg/m2
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PropofolTarget controlled infusion (TCI) with modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia. Monitoring and other anaesthetic procedures including the management of hypertension and hypotension in group P will be the same as group S. The only difference is that induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Oxygen and air would be given to provide a FiO2 of 30-50%. | Drug | Group P |
| SevofluranePropofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously for induction of general anaesthesia. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to maintain a BIS value of between 40-60. Intravenous remifentanil infusion between 0.1-0.2 mcg/kg/min will be given and this will be titrated to provide optimal haemodynamic parameters. | Drug | Group S |
Primary outcome
Pain assessed by numercial rating scales (NRS) pain scores
Time frame: at postoperative day 1
NRS pain scores (from 0-10, where 0 is the least satisfaction and 10 most satisfaction) will be recorded at rest and with coughing everyday.
3 secondary outcomes
PCA morphin consumption
Time frame: from postoperative day 0 until postoperative day 5
Dihydrocodeine use
Time frame: from postoperative day 0 until postoperative day 5
Side effects of analgesics
Time frame: from postoperative day 0 until postoperative day 5
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2022.
- Derived from this study: PubMed 37013472Wong SSC, Wang F, Chan TCW, Cheung CW. The analgesic effect of total intravenous anaesthesia with propofol versus inhalational anaesthesia for acute postoperative pain after hepatectomy: a randomized controlled trial. BMC Anesthesiol. 2023 Apr 3;23(1):112. doi: 10.1186/s12871-023-02063-7.
- Individual participant dataSharing planned: Undecided
Related trials for Postoperative Pain
RecruitingPhase 4
ESP Blocks for Posterior Spinal Fusion
Postoperative Pain
Recruiting
Effect of Cryotherapeutic and Nanotherapeutic Sodium Hypochlorite on Post-Operative Endodontic Pain.
Symptomatic Irreversible Pulpitis, Symptomatic Apical Periodontitis
RecruitingPhase 2
REctus Sheath Trial
Acute Pain, Postoperative Pain, Acute
Not yet recruiting
Effect of Pectoral Nerve Block (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Recovery and Chronic Post-Mastectomy Pain
Breast Cancer, Postoperative Pain
Active, not recruitingPhase 4
Effect of Dexmedetomidine on Postoperative Pain in Spinal Anesthesia for Cesarean Section at Assuit University Hospital
Cesarean Section
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Stanley SC Wong, MBBS principal investigator
The University of Hong Kong
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Propofol and Sevoflurane in people with Postoperative Pain, run by The University of Hong Kong at 2 sites in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain assessed by numercial rating scales (NRS) pain scores (time frame: at postoperative day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03597997, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2022.